TABLE 4.
Transitions between medication groups
| Medication group | Stability, annual range (%) | Most common transitions, annual range (%) | Other transitions per group, max (%) |
|---|---|---|---|
| No medication | 79–86 |
Metformin (3–8), Gliptins (1–6) |
2.1 |
| Metformin only | 88–91 |
Gliptins (3–8), SGLT2‐i (0–5) |
1.6 |
| Gliptins without SGLT2‐i or GLP−1 RA or insulin | 81–88 |
Long‐acting insulin (4–8), SGLT2‐i (1–11) |
2.0 |
| SGLT2‐i without GLP−1 RA or insulin | 84–96 | Long‐acting insulin (4–8) | 3.5 |
| GLP−1 RA without insulin | 83–91 | Long‐acting insulin (4–12), Gliptins (0–5) | 2.7 |
| Long‐acting insulin | 90–93 | Short‐acting insulin (5–7) | 1.3 |
| Short‐acting insulin | 90–94 | Long‐acting insulin (5–7) | 1.5 |
| Other | 67–75 |
Gliptins (8–19), Long‐acting insulin (2–6), Metformin only (3–5), SGLT2‐i (0–9), No medication (0–8) |
3.4 |